|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Droller MJ: Bladder cancer:
State-of-the-art care. CA Cancer J Clin. 48:269–284. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng L, Weaver AL, Leibovich BC, Ramnani
DM, Neumann RM, Scherer BG, Nehra A, Zincke H and Bostwick DG:
Predicting the survival of bladder carcinoma patients treated with
radical cystectomy. Cancer. 88:2326–2332. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Madsen P, Rasmussen HH, Leffers H, Honoré
B, Dejgaard K, Olsen E, Kiil J, Walbum E, Andersen AH, Basse B, et
al: Molecular cloning, occurrence, and expression of a novel
partially secreted protein ‘psoriasin’ that is highly up-regulated
in psoriatic skin. J Invest Dermatol. 97:701–712. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Algermissen B, Sitzmann J, LeMotte P and
Czarnetzki B: Differential expression of CRABP II, psoriasin and
cytokeratin 1 mRNA in human skin diseases. Arch Dermatol Res.
288:426–430. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Salama I, Malone PS, Mihaimeed F and Jones
JL: A review of the S100 proteins in cancer. Eur J Surg Oncol.
34:357–364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang WG, Watkins G, Douglas-Jones A and
Mansel RE: Psoriasin is aberrantly expressed in human breast cancer
and is related to clinical outcomes. Int J Oncol. 25:81–85.
2004.PubMed/NCBI
|
|
9
|
Moubayed N, Weichenthal M, Harder J,
Wandel E, Sticherling M and Glaser R: Psoriasin (S100A7) is
significantly up-regulated in human epithelial skin tumours. J
Cancer Res Clin Oncol. 133:253–261. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tripathi SC, Matta A, Kaur J, Grigull J,
Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R
and Siu KW: Nuclear S100A7 is associated with poor prognosis in
head and neck cancer. PLoS One. 5:e119392010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye L, Sun PH, Martin TA, Sanders AJ, Mason
MD and Jiang WG: Psoriasin (S100A7) is a positive regulator of
survival and invasion of prostate cancer cells. Urol Oncol.
31:1576–1583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu M, Ye L, Ruge F, Zhi X, Zhang L and
Jiang WG: The clinical significance of Psoriasin for non-small cell
lung cancer patients and its biological impact on lung cancer cell
functions. BMC Cancer. 12:5882012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Emberley ED, Alowami S, Snell L, Murphy LC
and Watson PH: S100A7 (psoriasin) expression is associated with
aggressive features and alteration of Jab1 in ductal carcinoma in
situ of the breast. Breast Cancer Res. 6:R308–R315. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shubbar E, Vegfors J, Carlstrom M,
Petersson S and Enerback C: Psoriasin (S100A7) increases the
expression of ROS and VEGF and acts through RAGE to promote
endothelial cell proliferation. Breast Cancer Res Treat. 134:71–80.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sneh A, Deol YS, Ganju A, Shilo K, Rosol
TJ, Nasser MW and Ganju RK: Differential role of psoriasin (S100A7)
in estrogen receptor α positive and negative breast cancer cells
occur through actin remodeling. Breast Cancer Res Treat.
138:727–739. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ostergaard M, Rasmussen HH, Nielsen HV,
Vorum H, Orntoft TF, Wolf H and Celis JE: Proteome profiling of
bladder squamous cell carcinomas: Identification of markers that
define their degree of differentiation. Cancer Res. 57:4111–4117.
1997.PubMed/NCBI
|
|
17
|
Celis JE, Rasmussen HH, Vorum H, Madsen P,
Honoré B, Wolf H and Orntoft TF: Bladder squamous cell carcinomas
express psoriasin and externalize it to the urine. J Urol.
155:2105–2112. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ostergaard M, Wolf H, Orntoft TF and Celis
JE: Psoriasin (S100A7): A putative urinary marker for the follow-up
of patients with bladder squamous cell carcinomas. Electrophoresis.
20:349–354. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rasmussen HH, Orntoft TF, Wolf H and Celis
JE: Towards a comprehensive database of proteins from the urine of
patients with bladder cancer. J Urol. 155:2113–2119. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dyrskjot L, Kruhoffer M, Thykjaer T,
Marcussen N, Jensen JL, Møller K and Ørntoft TF: Gene expression in
the urinary bladder: A common carcinoma in situ gene expression
signature exists disregarding histopathological classification.
Cancer Res. 64:4040–4048. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lindgren D, Sjödahl G, Lauss M, Staaf J,
Chebil G, Lövgren K, Gudjonsson S, Liedberg F, Patschan O, Månsson
W, et al: Integrated genomic and gene expression profiling
identifies two major genomic circuits in urothelial carcinoma. PLoS
One. 7:e388632012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oyasu R: World health organization and
international society of urological pathology classification and
two-number grading system of bladder tumors. Cancer. 88:1509–1512.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Glaser R, Harder J, Lange H, Bartels J,
Christophers E and Schroder JM: Antimicrobial psoriasin (S100A7)
protects human skin from Escherichia coli infection. Nat Immunol.
6:57–64. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Bunston C, Hodson N, Resaul J, Sun
PH, Cai S, Chen G, Gu Y, Satherley LK, Bosanquet DC, et al:
Psoriasin promotes invasion, aggregation and survival of pancreatic
cancer cells; association with disease progression. Int J Oncol.
50:1491–1500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Zhao Q, Chen Y, Wang Y, Gao S,
Mao Y, Li M, Peng A, He D and Xiao X: Selective expression of
S100A7 in lung squamous cell carcinomas and large cell carcinomas
but not in adenocarcinomas and small cell carcinomas. Thorax.
63:352–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Winston J and Wolf R: Psoriasin (S100A7)
promotes migration of a squamous carcinoma cell line. J Dermatol
Sci. 67:205–207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ellenrieder V, Alber B, Lacher U, Hendler
SF, Menke A, Boeck W, Wagner M, Wilda M, Friess H, Büchler M, et
al: Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int
J Cancer. 85:14–20. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Morgan MR, Jazayeri M, Ramsay AG, Thomas
GJ, Boulanger MJ, Hart IR and Marshall JF: Psoriasin (S100A7)
associates with integrin β6 subunit and is required for
αvβ6-dependent carcinoma cell invasion. Oncogene. 30:1422–1435.
2011. View Article : Google Scholar : PubMed/NCBI
|
